<DOC>
	<DOC>NCT01926912</DOC>
	<brief_summary>The purpose of this study to evaluate safety, tolerability, treatment outcomes, appropriate use and pattern of paliperidone palmitate usage in participants with schizophrenia in the hospital setting.</brief_summary>
	<brief_title>A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting</brief_title>
	<detailed_description>This is a prospective (look forward using periodic observations collected predominantly following patient enrollment), multicenter, observational study (a type of study in which participants are observed or certain outcomes are measured). This study will consist of 6-week observational period during which data will be collected for participants who are hospitalized due to schizophrenia exacerbation and are receiving treatment with paliperidone palmitate (treatment initiated within 3 weeks after admission to hospital). The participant satisfaction will be evaluated at week 6 (or early discontinuation). Safety evaluations will include body weight, extrapyramidal symptom (eg, inability to initiate movement and inability to remain motionless) rating scale scores, concomitant therapy and assessment of adverse events.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Participants diagnosed with schizophrenia Participant admitted to hospital due to an exacerbation of their schizophrenia prior to any studyrelated activity Participant may, in the opinion of the participating physician, benefit from treatment with paliperidone palmitate which will be initiated within 3 weeks after admission to hospital Participant has a known hypersensitivity to paliperidone or risperidone Participant has previously been treated with paliperidone palmitate Participant has a history of neuroleptic malignant syndrome Participant was on clozapine or has previously been treated with any longacting injectable antipsychotic during the last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone Palmitate</keyword>
	<keyword>Hospital setting</keyword>
	<keyword>Schizophrenic Disorders</keyword>
</DOC>